First launch of UTIPRO® PLUS AF in EUROPE
We are pleased to announce the launch of UTIPRO® PLUS AF in Portugal. Portugal is the first European country in which UTIPRO® PLUS AF has been
Noventure is proud to announce the launch of XILAPLUS® in Estonia, Latvia and Lithuania by our partner company Miecys
Noventure is proud to announce the launch of XILAPLUS® in Estonia, Latvia and Lithuania by our partner company Miecys XILAPLUS® is specifically formulated for the
UTIPRO® PLUS AF strengthens its presence in EUROPE
We are pleased to announce the launch of UTIPRO® PLUS AF in the Republic of Ireland. UTIPRO® PLUS AF, in its composition free from ingredients
We are proud to announce the publication of the clinical trial “Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children”
Santos J. et al. Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children.Expert Rev Gastroenterol Hepatol: 2020 Oct 19;1-7.
Uncomplicated Urinary Tract Infection in Adults – Noventure new Publication
We are glad inform you about a recent publication to further support the usefulness of mucoprotection in the relief of symptoms and in the prevention
Gelatin tannate versus other antidiarrheal medication in children with acute gastroenteritis: a retrospective, observational study
Elena D Serban & Mihai Manolache; Journal of Comparative Effectiveness ResearchVol. 8, No. 3 Journal of Comparative Effectiveness ResearchVol. 8, No. 3 Publication of a
A randomized controlled trial comparing a xyloglucan-based nasal spray with saline in adults with symptoms of rhinosinusitis.
Allegrini A et al. Current Medical Research and Opinion 2017. June 10: 1-17 Background: This study assessed the efficacy, safety and tolerability of a xyloglucan-based
Congresses: Noventure participates at the third edition of FNM
Gelsectan®, Noventure´s new medical device intended for IBS-D, was presented at Noventure´s stand during the 3rd Meeting of the Federation of Neurogastroenterology and Motility, from
AGA Abstracts Tu1254 – Protective Effect of Mucoprotectants and Prebiotic Combination on Gut Barrier Impairment and Visceral Hypersensitivity Induced by an Acute Stress in Rat
HeleneEutamene, FannyPlacide, ValerieTondereau, VassiliaTheodorou https://doi.org/10.1016/S0016-5085(18)33080-4 BACKGROUND: Irritable Bowel Syndrome (IBS) is a common disorder characterized by visceral hypersensitivity and increased intestinal permeability. Stressful events can
Rhinosectan® Launched In Spain
We are pleased to announce the launch of Rhinosectan® in its first market, Spain. Rhinosectan® is based on Xyloglucan, a mucomimetic agent that forms a
